Published in Hepatitis Weekly, March 19th, 2001
Physicians commonly give interferon (IFN) to HCV patients as a first choice of treatment. However, some patients fail to benefit from IFN. Their viral levels remain high even after extended periods of taking treatments.
A controlled study performed at Saint Louis University School of Medicine indicates a second round of interferon therapy that adds ribavirin to the regimen could benefit a majority of initial non-responders.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly